4DMedical gains U.S. CMS reimbursement for CT:VQ™

3 September 2025

Highlights

- U.S. Centers for Medicare & Medicaid Services (CMS) confirm reimbursement for CT:VQ™, accelerating the path to broad market adoption
- CT:VQ™ will be reimbursed as a New Technology Ambulatory Payment Classification (APC) at US$650.50 per scan under the Hospital Outpatient Prospective Payment System (OPPS)
- CMS will pay the $650.50 CT:VQ™ reimbursement on top of the healthcare provider's standard chest CT scan payment
- CT:VQ™ reduces the cost of delivering care, particularly relevant for inpatient facilities covered under the Diagnosis-Related Group (DRG)-based Prospective Payment System (PPS)
- Hospitals and imaging centres can now confidently integrate CT:VQ™ into standard clinical workflows, knowing they will receive reliable payment through established systems

---

Melbourne, Australia, 3 September 2025: 4DMedical Limited (ASX: 4DX, "4DMedical" or the "Company"), a global leader in respiratory imaging technology, today announces the U.S. Centers for Medicare & Medicaid Services (CMS) have confirmed that reimbursement for the Company's groundbreaking CT-based ventilation-perfusion software, CT:VQ™, falls under Category III Current Procedural Terminology (CPT®) codes 0721T and 0722T, and will be paid at US$650.50 per scan, effective immediately.

Clear reimbursement pathway to accelerate market adoption

CMS has established clear reimbursement for CT:VQ™, which is crucial for widespread market adoption. Hospitals and imaging centres can now confidently integrate this technology into their standard workflows, knowing they'll receive reliable payment through established systems.

Financial benefits for healthcare facilities

The technology offers improved economics for both outpatient and inpatient settings. Under the Hospital Outpatient Prospective Payment System (OPPS), CMS will pay US$650.50 per CT:VQ™ scan through a New Technology APC designation. This payment is in addition to the standard chest CT scan fee, creating a predictable revenue model for providers.

For inpatient settings using the Diagnosis-Related Group (DRG) payment system, CT:VQ™ creates opportunities to reduce costs while maintaining the highest quality care. The technology requires no expensive new infrastructure and streamlines existing workflows.

Patient benefits

For patients, CT:VQ™ delivers comprehensive lung function assessment without radioactive exposure or contrast agents, using standard CT scans they may already be receiving. This eliminates the need for separate nuclear medicine appointments while providing the same diagnostic information through a faster, safer procedure. This breakthrough extends advanced diagnostic capabilities to healthcare settings that previously lacked nuclear medicine facilities, improving access across diverse care environments.

For personal use only

Commercial impact

The reimbursement structure makes CT:VQ™ both clinically valuable and economically enticing. Medicare's support enables imaging facilities to offer advanced lung imaging without additional capital investment or procedural complexity, positioning the technology for broad market adoption.

4DMedical MD/CEO and Founder Andreas Fouras said:

CMS's confirmation that CT:VQ™ qualifies for reimbursement of US$650.50, on top of existing chest CT payments, is a game changer. Certainty around reimbursement, on the heels of our FDA 510(k) clearance, means CT:VQ™ is ready for immediate and broad commercial integration. We've cleared regulatory and reimbursement hurdles in quick succession, removing the biggest barriers to adoption and bringing us closer to redefining functional lung imaging at scale.

Improved accessibility of CT:VQ™ has huge potential to improve healthcare. From hospitals without Nuclear Imaging departments, to surgeons and interventional pulmonologists unable to assess their patients before treatment, many stand to benefit from VQ assessment delivered from a routine CT. This reimbursement reinforces the opportunity for more patients being able to benefit from this technology.

With both FDA approval and Medicare reimbursement confirmed, and with our cash position now secure, 4DMedical is perfectly positioned to launch CT:VQ™ commercially across the United States. The Company will accelerate engagements with leading hospital groups, imaging networks, and academic institutions, providing them with access to this revolutionary software that transforms a routine non-contrast CT into a powerful functional assessment.

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate
Investor Relations
investor.relations@4dmedical.com

Administration
Company Secretary
companysecretary@4dmedical.com

Media Enquiries
4Dmedia@4dmedical.com

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionizing respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology®** transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS®)**, **CT LVAS™**, and the ground-breaking **CT:VQ™** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalized patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com

For personal use only

©4DMedical Limited